<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681174</url>
  </required_header>
  <id_info>
    <org_study_id>ANEST-TOR-01</org_study_id>
    <nct_id>NCT00681174</nct_id>
  </id_info>
  <brief_title>Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery</brief_title>
  <official_title>Preoperative Controlled-Release Oxycodone or Intraoperative Morphine As Transition Opioid After Intravenous Anesthesia For Video-Assisted Thoracic Surgery: a Randomized, Double-blind, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main hypothesis of this study is that preoperative administration of controlled-release
      (CR) oxycodone may reduce acute postoperative pain and improve time to discharge from the
      post-anesthesia care unit in patients undergoing video-assisted thoracoscopy for spontaneous
      pneumothorax.

      The study drug will be compared with intravenous morphine administered 30 minutes before the
      end of anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although spontaneous pneumothorax may be treated conservatively by simple observation or
      chest tube insertion, up to 50% of patients treated conservatively may experience recurrence
      in subsequent months or years.

      Video-assisted thoracic surgery (VATS) is a minimally-invasive surgical approach to treat
      spontaneous pneumothorax and reduce the risk of recurrence. Compared to open thoracotomy,
      VATS may facilitate a faster recovery and lead to earlier home discharge.

      Totally-intravenous anesthesia (TIVA) with propofol and remifentanil is a useful anesthetic
      technique for VATS, as the drugs are rapidly eliminated after the end of the procedure,
      leading to fast recovery from anesthesia.

      One drawback of ultra-short-acting opioid remifentanil is residual hyperalgesia after the end
      of the infusion, particularly after VATS, which is associated with relatively short but
      intense pain after surgery.

      Intravenous morphine, administered just before the end of anesthesia, is the typical choice
      for pain relief after TIVA. However, this drug may require repeated titration and may be
      associated with postoperative nausea and vomiting, itchiness or drowsiness in the early
      postoperative period.

      Oxycodone, another opioid, is available in an oral controlled-release (CR) formulation which
      grants relatively constant plasma levels of the drug after 1 h of administration.

      The investigators hypothesize that administration of CR oxycodone 20 mg 1 hour before surgery
      may lead to better recovery parameters in the post-anesthesia care unit, thus granting
      earlier discharge to the surgical ward.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to enroll sufficient patients by expected deadline.
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption (intravenous titration in PACU + i.v. patient-controlled pump usage)</measure>
    <time_frame>48 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity as measured on a visual analog scale</measure>
    <time_frame>1 h after end of anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from post-anesthesia care unit (Aldrete score &gt;9)</measure>
    <time_frame>0-12 h after end of anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea or vomiting</measure>
    <time_frame>48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory depression (SpO2 &lt; 92% or respiratory rate &lt;8)</measure>
    <time_frame>48 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Anesthesia Recovery Period</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CROxy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive controlled-release oxycodone 1 h pre-operatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone</intervention_name>
    <description>20 mg p.o. 1 h before the start of anesthesia</description>
    <arm_group_label>CROxy</arm_group_label>
    <other_name>controlled-release oxycodone</other_name>
    <other_name>CR oxycodone</other_name>
    <other_name>OxyContin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paravertebral block</intervention_name>
    <description>Three injections of 0.5% ropivacaine, 5 ml each
Injections at the T5, T6 and T7 levels
A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be &quot;walked off&quot; the process and the injection will be made 1 cm deeper.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>CROxy</arm_group_label>
    <other_name>Paravertebral nerve block</other_name>
    <other_name>Naropin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Plasma concentration target-controlled infusion based on bispectral index values
Acceptable range of concentrations: 2-4 µg/mL
Target bispectral index values: 40-60
Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>CROxy</arm_group_label>
    <other_name>Propofol TCI</other_name>
    <other_name>target-controlled infusion</other_name>
    <other_name>TIVA</other_name>
    <other_name>TCI-TIVA</other_name>
    <other_name>TIVA-TCI</other_name>
    <other_name>Diprivan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min
Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)
Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.
Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>CROxy</arm_group_label>
    <other_name>TIVA</other_name>
    <other_name>Ultiva®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>CROxy</arm_group_label>
    <other_name>Acetaminophen</other_name>
    <other_name>Perfalgan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Patient-controlled intravenous infusion pump (IV-PCA).
50 mg morphine in 50 ml saline solution (1 mg/ml)
Incremental dose: 1 mg
Lock-out time: 8 min
Limit: 40 mg in 4 h
Background infusion: none</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>CROxy</arm_group_label>
    <other_name>PCA</other_name>
    <other_name>IVPCA</other_name>
    <other_name>IV-PCA</other_name>
    <other_name>PCA-IV</other_name>
    <other_name>Patient-controlled analgesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for video-assisted thoracic surgery for clinical diagnosis of
             spontaneous pneumothorax

          -  Must be able to swallow tablets 1 h before surgery

          -  American Society of Anesthesiologists (ASA) physical status class I or II

        Exclusion Criteria:

          -  Known allergy or other contraindications to study drugs

          -  Acute myocardial infarction ≤6 months before enrollment

          -  Serum creatinine &gt; 2 mg/dL

          -  Body mass index (BMI) &gt; 30

          -  Diagnosis of psychiatric disorders

          -  Known or possible pregnancy

          -  Epilepsy

          -  Chronic opioid therapy or abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Fanelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Section of Anesthesiology and Critical Care, Dept. of Anesthesiology, University of Parma, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Berti, MD</last_name>
    <role>Study Director</role>
    <affiliation>II Unit of Anesthesia, Critical Care and Pain Medicine, University Hospital of Parma, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franca Bridelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>II Unit of Anesthesia, Critical Care and Pain Medicine, University Hospital of Parma, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital / Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Noppen M, Baumann MH. Pathogenesis and treatment of primary spontaneous pneumothorax: an overview. Respiration. 2003 Jul-Aug;70(4):431-8. Review.</citation>
    <PMID>14512683</PMID>
  </reference>
  <reference>
    <citation>Hansen EG, Duedahl TH, Rømsing J, Hilsted KL, Dahl JB. Intra-operative remifentanil might influence pain levels in the immediate post-operative period after major abdominal surgery. Acta Anaesthesiol Scand. 2005 Nov;49(10):1464-70.</citation>
    <PMID>16223391</PMID>
  </reference>
  <reference>
    <citation>Sunshine A, Olson NZ, Colon A, Rivera J, Kaiko RF, Fitzmartin RD, Reder RF, Goldenheim PD. Analgesic efficacy of controlled-release oxycodone in postoperative pain. J Clin Pharmacol. 1996 Jul;36(7):595-603.</citation>
    <PMID>8844441</PMID>
  </reference>
  <reference>
    <citation>Vogt A, Stieger DS, Theurillat C, Curatolo M. Single-injection thoracic paravertebral block for postoperative pain treatment after thoracoscopic surgery. Br J Anaesth. 2005 Dec;95(6):816-21. Epub 2005 Sep 30.</citation>
    <PMID>16199417</PMID>
  </reference>
  <reference>
    <citation>Kaya FN, Turker G, Basagan-Mogol E, Goren S, Bayram S, Gebitekin C. Preoperative multiple-injection thoracic paravertebral blocks reduce postoperative pain and analgesic requirements after video-assisted thoracic surgery. J Cardiothorac Vasc Anesth. 2006 Oct;20(5):639-43. Epub 2006 Aug 8.</citation>
    <PMID>17023279</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>January 5, 2012</last_update_submitted>
  <last_update_submitted_qc>January 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Parma</investigator_affiliation>
    <investigator_full_name>Guido Fanelli</investigator_full_name>
    <investigator_title>Professor of Anesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Care, Postoperative</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Analgesics, Opioid</keyword>
  <keyword>Morphine</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Anesthesia, Regional</keyword>
  <keyword>Anesthesia, Intravenous</keyword>
  <keyword>Preanesthetic Medication</keyword>
  <keyword>Analgesia, Patient-Controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

